Maternal vaccination primes infant protection through the transplacental transfer of maternal antibodies, chiefly immunoglobulin G, during the third trimester. These antibodies reduce immediate risk of severe disease for newborns against pathogens such as influenza, pertussis, and tetanus. Public health authorities including the World Health Organization and the Centers for Disease Control and Prevention recommend maternal vaccination to close the vulnerability gap before the infant completes primary immunizations. Authors who have analyzed these trade-offs include Paul A. Offit Children's Hospital of Philadelphia and Saad B. Omer Emory University, who discuss mechanisms and policy implications in peer-reviewed reviews and guidance.
Biological mechanisms and causes of altered infant responses
Maternal antibodies can directly neutralize vaccine antigens or form immune complexes that change antigen presentation, producing a phenomenon often called blunting of infant vaccine responses. Mechanisms include epitope masking that prevents B cell recognition and Fc receptor–mediated feedback that dampens infant antibody production. The magnitude and duration of blunting vary by pathogen, vaccine type, timing of maternal immunization, and the infant’s own vaccination schedule. Blunting is more consistently observed with live attenuated measles virus and with some inactivated or acellular vaccines than with others.
Consequences for protection and policy
Clinically, the most important consequence is a balance between immediate protection and potentially reduced short-term serologic responses to early infant doses. For diseases with high early-life severity such as pertussis and influenza, the benefit of maternal vaccination in preventing hospitalization and death overwhelmingly outweighs the risk of transiently lower antibody titers after infant immunization. Long-term immunity is usually preserved because later booster doses and natural exposure broaden responses. Public health recommendations therefore prioritize maternal immunization during pregnancy, especially in regions where early infant exposure and severe disease are common.
Cultural, environmental, and territorial factors shape outcomes. In low-resource settings with high pathogen circulation and limited neonatal care, the protective effect of maternal antibodies can be lifesaving. In settings with high vaccine uptake and low transmission, concerns about blunting may influence the choice of vaccine formulation or timing but rarely change the overall recommendation to vaccinate pregnant people. Ongoing surveillance and context-specific studies remain essential to tailor schedules and to reassure communities about safety and effectiveness.